Japanese
TitleIn-111標識モノクローナル抗体96.5およびZME 018によるヒトメラノーマのイメージングについて
Subtitle原著
Authors小山田日吉丸*, 石原和之**, 福喜多博義***, 早坂健一**
Authors(kana)
Organization*癌研究会附属病院アイソトープ部, **国立がんセンター皮膚科, ***放射線診断部
Journal核医学
Volume26
Number12
Page1503-1512
Year/Month1989/12
Article原著
Publisher日本核医学会
Abstract「要旨」われわれは, 米国Hybritech社から帝人株式会社を介して入手した2種類の抗ヒト・メラノーマ・マウス・モノクローナル抗体 (96.5とZME 018) をそれぞれIn-111で標識し, イメージングを試みたので, その結果について報告した. 対象は, 96.5についてはメラノーマ11例, 基底細胞癌1例, ZME 018についてはメラノーマ6例, 基底細胞癌1例であり, 両薬剤による画像およびそれらの体内挙動についての比較検討を行った. メラノーマについてはIn-111-96.5は31病巣中24病巣を描出し, In-111-ZME 018はoccult lesion 2病巣を含む10病巣中9病巣を描出した. しかし, 後者については病巣数が少ないので両者の陽性率を単純に比較することはできない. 基底細胞癌は両抗体でともに, ごく淡かったが描出された. 体内挙動の差は両抗体の間でごく僅かなものと考えられた. あわせて治療への応用についても考察を加えた.
Practice臨床医学：一般
KeywordsMonoclonal antibody, Radioimmunoimaging, Radioimmunotherapy, Malignant melanoma, Indium-111.
English
TitleRadioimmunoimaging of Malignant Melanoma with In-111-Labeled Monoclonal Antibodies 96.5 and ZME 018
Subtitle
AuthorsHiyoshimaru OYAMADA*, Kazuyuki ISHIHARA**, Hiroyoshi FUKUKITA***, Kenichi HAYASAKA**
Authors(kana)
Organization*Department of Nuclear Medicine, Cancer Institute Hospital, **Department of Dermatology, National Cancer Center Hospital, ***Department of Diagnostic Radiology, National Cancer Center Hospital
JournalThe Japanese Journal of nuclear medicine
Volume26
Number12
Page1503-1512
Year/Month1989/12
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary] This paper includes the results of imaging and kinetic studies on two kinds of In-111-labeled monoclonal antibodies (MoAbs) , 96.5 and ZME 018, which are known to have capability of recognizing different surface antigens present in malignant melanoma cells. These MoAbs were supplied by Hybritech Inc. through Teijin Ltd. The former MoAb (96.5) was used on 11 cases of malignant melanoma and one case of basal cell carcinoma, and the latter MoAb (ZME 018) was used on 6 cases of malignant melanoma and one case of basal cell carcinoma. As for the malignant melanoma, the results obtained from both patients groups were compared to each other. Twenty-four out of 31 lesions in the former group and 9 (including 2 occult lesions) out of 10 lesions in the latter group were visualized. However, these positive ratios can not be compared to each other because of the very small number of the lesions in the latter group. One basal cell carcinoma each from both groups were faintly visualized. Distribution patterns of these In-111-labeled MoAbs were similar to each other. Except for the first two cases in the former group, labeling efficiencies were 94.3+-0.7% with 96.5 and 92.0+-0.6% with ZME 018. Urinary excretions on the 1st day were 8.3+-0.9% with the former and 9.3+-0.3% with the latter. However, there was no statistical difference. Following the 1st day, these values changed at the level of several Per cent from the 2nd to 4th day, showing a subtle and gradual rise and slightly lower values for In-111-ZME 018. But, again, there were no statistical differences. Whole body retention curves in both groups were similar to each other, and blood clearance curves were also found similar in both groups. HAMA titers were checked in all patients and were found elevated after the administration in most of the cases. Although the number of patients tested in this series is small, especially with In-111-ZME 018, both MoAbs labeled with In-111 seem to be equally capable of visualizing malignant melanoma. Possibility of the treatment of malignant melanoma with this kind of technique was also discussed.
PracticeClinical medicine
KeywordsMonoclonal antibody, Radioimmunoimaging, Radioimmunotherapy, Malignant melanoma, Indium-111.

【全文PDF】